Given the aforementioned cell line data, the addition of DNA methyltransferase (DNMT) inhibitors would appear to be a reasonable approach, particularly in tsMHC-II negative colorectal cancer and given that DNMT inhibition alone can reverse the inhibitory histone marks of deactylated histone H3 and methylated H3K9 (21). Here, DNMT1 is linked to colorectal cancer.